Chronotropic Support: Isoprenaline vs Dopamine
For patients requiring chronotropic support, isoprenaline (isoproterenol) is the preferred agent over dopamine, provided the patient has a low likelihood of coronary ischemia. 1
Rationale Based on Guidelines
The 2018 ACC/AHA/HRS Bradycardia Guidelines provide clear guidance on this decision 1:
- Both agents receive a Class IIb recommendation (may be considered) for symptomatic bradycardia or hemodynamic compromise in sinus node dysfunction
- However, the guideline specifically emphasizes that these agents should only be used "in patients at low likelihood of coronary ischemia"
Key Pharmacologic Differences
Isoproterenol:
- Pure nonselective beta-agonist with both chronotropic and inotropic effects
- No vasopressor effect - actually causes vasodilation
- Directly enhances sinus and AV nodal function
- Dosing: 20-60 mcg IV bolus or 1-20 mcg/min infusion 1, 2
- Critical caveat: Monitor closely for ischemic chest pain due to increased myocardial oxygen demand without coronary vasoconstriction 1
Dopamine:
- Mixed alpha, beta, and dopaminergic effects that are dose-dependent
- At 5-20 mcg/kg/min: chronotropic and inotropic effects predominate
- Higher doses cause vasoconstriction and increase arrhythmia risk 1
- Dosing: Start at 5 mcg/kg/min, increase by 5 mcg/kg/min every 2 minutes 1, 3
- Major concern: Doses >20 mcg/kg/min associated with profound vasoconstriction and proarrhythmias 1
Clinical Decision Algorithm
Choose Isoproterenol when:
- Patient needs pure chronotropic support
- Blood pressure is adequate or elevated
- No evidence of coronary artery disease or active ischemia
- Peripheral vasoconstriction is undesirable
Choose Dopamine when:
- Patient requires both chronotropic support AND blood pressure support
- Renal perfusion enhancement is desired (at lower doses)
- However, recognize that higher doses needed for chronotropy increase arrhythmia risk
Critical Safety Considerations
Isoproterenol's main hazard is increasing myocardial oxygen consumption without providing coronary perfusion pressure, potentially precipitating ischemia 1. This makes it contraindicated in patients with known or suspected coronary disease.
Dopamine's main hazards include:
- Dose-dependent vasoconstriction at higher levels
- Increased arrhythmia risk, particularly at doses >20 mcg/kg/min 1
- Recent evidence suggests dopamine may be associated with worse outcomes compared to norepinephrine in shock states 4, 5
Supporting Evidence
Research demonstrates that isoproterenol is more effective as a pure chronotrope 6, 7. In pediatric cardiac surgery patients, isoproterenol was more effective than dopamine at increasing cardiac index due to its ability to increase heart rate and decrease systemic vascular resistance 6. Comparative studies show isoproterenol produces greater chronotropic effects than dopamine at equivalent inotropic doses 7.
First-Line Consideration
Before either agent, try atropine first (Class IIa recommendation) 1:
- Dosing: 0.5-1 mg IV, may repeat every 3-5 minutes to maximum 3 mg
- Safer initial approach for symptomatic bradycardia
- Exception: Do not use in heart transplant patients without autonomic reinnervation (Class III: Harm) 1
The bottom line: Isoproterenol is the superior chronotrope when ischemia risk is low; dopamine should be reserved for situations requiring combined chronotropic and vasopressor support, but recognize its limitations and arrhythmogenic potential at higher doses.